DK3080100T3 - Hæmmere af lysinspecifik demethylase-1 - Google Patents
Hæmmere af lysinspecifik demethylase-1 Download PDFInfo
- Publication number
- DK3080100T3 DK3080100T3 DK14868829.4T DK14868829T DK3080100T3 DK 3080100 T3 DK3080100 T3 DK 3080100T3 DK 14868829 T DK14868829 T DK 14868829T DK 3080100 T3 DK3080100 T3 DK 3080100T3
- Authority
- DK
- Denmark
- Prior art keywords
- lysine
- inhibitors
- specific demethylase
- demethylase
- specific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361914927P | 2013-12-11 | 2013-12-11 | |
PCT/US2014/069562 WO2015089192A1 (en) | 2013-12-11 | 2014-12-10 | Inhibitors of lysine specific demethylase-1 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3080100T3 true DK3080100T3 (da) | 2023-02-06 |
Family
ID=53371806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK14868829.4T DK3080100T3 (da) | 2013-12-11 | 2014-12-10 | Hæmmere af lysinspecifik demethylase-1 |
Country Status (16)
Country | Link |
---|---|
US (3) | US9944636B2 (da) |
EP (2) | EP4257591A3 (da) |
JP (1) | JP6430512B2 (da) |
CA (2) | CA2933480C (da) |
DK (1) | DK3080100T3 (da) |
ES (1) | ES2935746T3 (da) |
FI (1) | FI3080100T3 (da) |
HR (1) | HRP20230086T1 (da) |
HU (1) | HUE061252T2 (da) |
LT (1) | LT3080100T (da) |
MX (2) | MX2016007585A (da) |
PL (1) | PL3080100T3 (da) |
PT (1) | PT3080100T (da) |
RS (1) | RS63939B1 (da) |
SI (1) | SI3080100T1 (da) |
WO (1) | WO2015089192A1 (da) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3392244A1 (en) | 2014-02-13 | 2018-10-24 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
LT3105218T (lt) | 2014-02-13 | 2019-12-10 | Incyte Corp | Ciklopropilaminai kaip lsd1 inhibitoriai |
WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
HUE045725T2 (hu) | 2014-02-13 | 2020-01-28 | Incyte Corp | Ciklopropilaminok mint LSD1 inhibitorok |
TWI676620B (zh) * | 2014-05-01 | 2019-11-11 | 美商賽基昆堤塞爾研發公司 | 離胺酸特異性去甲基酶-1之抑制劑 |
HUE050564T2 (hu) | 2014-06-27 | 2020-12-28 | Celgene Quanticel Res Inc | Lizinspecifikus demetiláz-1 inhibitorai |
US9902719B2 (en) * | 2014-07-03 | 2018-02-27 | Celgene Quanticel Research, Inc. | Inhibitors of lysine specific demethylase-1 |
WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
SG11201701683XA (en) * | 2014-09-05 | 2017-04-27 | Celgene Quanticel Res Inc | Inhibitors of lysine specific demethylase-1 |
MA51438A (fr) | 2015-04-03 | 2021-04-14 | Incyte Corp | Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1 |
SG10201911989SA (en) | 2015-06-12 | 2020-02-27 | Oryzon Genomics Sa | Biomarkers associated with lsd1 inhibitors and uses thereof |
WO2017013061A1 (en) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
MX2018001706A (es) | 2015-08-12 | 2018-09-06 | Incyte Corp | Sales de un inhibidor de dimetilasa 1 especifica para lisina (lsd1). |
US10059668B2 (en) | 2015-11-05 | 2018-08-28 | Mirati Therapeutics, Inc. | LSD1 inhibitors |
FI3381896T3 (fi) * | 2015-11-27 | 2023-04-21 | Taiho Pharmaceutical Co Ltd | Bifenyyliyhdiste tai sen suola |
CA3009805C (en) | 2015-12-29 | 2023-10-17 | Mirati Therapeutics, Inc. | Lsd1 inhibitors |
SG11201807965YA (en) | 2016-03-15 | 2018-10-30 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for use in the treatment of solid tumors |
JP2019512546A (ja) | 2016-03-16 | 2019-05-16 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Kdm1a標的会合を決定するための方法、およびそれに有用な化学プローブ |
US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
CN109414410B (zh) | 2016-04-22 | 2022-08-12 | 因赛特公司 | Lsd1抑制剂的制剂 |
CN105924397B (zh) * | 2016-04-29 | 2017-11-24 | 河南省农业科学院植物保护研究所 | 一种1,5‑二芳基‑3‑甲酸酯吡唑类化合物、制备方法及用途 |
US20190256930A1 (en) | 2016-11-03 | 2019-08-22 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
WO2018083138A1 (en) | 2016-11-03 | 2018-05-11 | Oryzon Genomics, S.A. | Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents |
JP7352284B2 (ja) * | 2017-05-15 | 2023-09-28 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン | LSD-1インヒビターとしてのピロロ〔2,3-c〕ピリジン及び関連類似体 |
MA50466A (fr) | 2017-05-26 | 2020-09-02 | Taiho Pharmaceutical Co Ltd | Nouveau composé de biphényle ou sel de celui-ci |
EP3632443B1 (en) * | 2017-05-26 | 2023-06-07 | Taiho Pharmaceutical Co., Ltd. | Anti-tumor effect potentiator using a biphenyl compound |
JP6915056B2 (ja) | 2017-05-31 | 2021-08-04 | 大鵬薬品工業株式会社 | Insm1の発現に基づくlsd1阻害剤の治療効果の予測方法 |
WO2019025588A1 (en) | 2017-08-03 | 2019-02-07 | Oryzon Genomics, S.A. | METHODS OF TREATING ALTERATIONS IN BEHAVIOR |
TWI794294B (zh) | 2017-09-13 | 2023-03-01 | 南韓商韓美藥品股份有限公司 | 吡唑衍生化合物及其用途 |
WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
EP3941465A1 (en) | 2019-03-20 | 2022-01-26 | Oryzon Genomics, S.A. | Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat |
SG11202109159VA (en) | 2019-03-20 | 2021-10-28 | Oryzon Genomics Sa | Methods of treating borderline personality disorder |
JP2022546908A (ja) | 2019-07-05 | 2022-11-10 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Kdm1a阻害剤を使用した小細胞肺がんの個別化された処置のためのバイオマーカーおよび方法 |
CN114105950B (zh) * | 2020-08-31 | 2022-09-06 | 南京明德新药研发有限公司 | 吡唑类化合物及其应用 |
EP4319732A1 (en) | 2021-04-08 | 2024-02-14 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors for treating myeloid cancers |
WO2023217758A1 (en) | 2022-05-09 | 2023-11-16 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
WO2023217784A1 (en) | 2022-05-09 | 2023-11-16 | Oryzon Genomics, S.A. | Methods of treating nf1-mutant tumors using lsd1 inhibitors |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5550147A (en) * | 1992-02-05 | 1996-08-27 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same |
US7087614B2 (en) * | 2001-06-19 | 2006-08-08 | Bristol-Myers Squibb Co. | Pyrimidine inhibitors of phosphodiesterase (PDE) 7 |
EP1490365B1 (en) * | 2002-03-28 | 2010-02-10 | Eisai R&D Management Co., Ltd. | Azaindoles as inhibitors of c-jun n-terminal kinases |
ATE527250T1 (de) * | 2002-11-21 | 2011-10-15 | Novartis Ag | 2,4,6-trisubstituierten pyrimidinen als phosphotidylinositol (pi) 3-kinase inhibitoren und deren verwendung zur behandlung von krebs |
TW200526641A (en) * | 2003-12-26 | 2005-08-16 | Daiichi Seiyaku Co | Amidopyrazole derivatives |
WO2007006581A2 (en) | 2005-07-13 | 2007-01-18 | Universitätsklinikum Freiburg | Targeting lsd1 for use in identifying and/or scoring prostate cancer and for controlling anrogen receptor-dependent gene expression |
EA200870217A1 (ru) * | 2006-01-30 | 2009-02-27 | Экселиксис, Инк. | 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции |
CN104030990B (zh) * | 2007-03-12 | 2017-01-04 | Ym生物科学澳大利亚私人有限公司 | 苯基氨基嘧啶化合物及其用途 |
ES2597903T3 (es) * | 2008-07-29 | 2017-01-24 | Boehringer Ingelheim International Gmbh | 5-Alquinil-pirimidinas |
WO2010046780A2 (en) * | 2008-10-22 | 2010-04-29 | Institut Pasteur Korea | Anti viral compounds |
TWI435874B (zh) * | 2008-10-31 | 2014-05-01 | Toray Industries | 環己烷衍生物及其醫藥用途 |
EP2258865A1 (en) * | 2009-06-05 | 2010-12-08 | Universitätsklinikum Freiburg | Lysine-specific demethylase 1 (LSD1) is a biomarker for breast cancer |
EP2258858A1 (en) | 2009-06-05 | 2010-12-08 | Universitätsklinikum Freiburg | Transgenic LSD1 animal model for cancer |
US9708255B2 (en) * | 2009-08-18 | 2017-07-18 | Robert A. Casero | (bis)urea and (bis)thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders |
TW201111378A (en) * | 2009-09-11 | 2011-04-01 | Bayer Schering Pharma Ag | Substituted (heteroarylmethyl) thiohydantoins |
WO2011143057A1 (en) * | 2010-05-11 | 2011-11-17 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
US9006449B2 (en) * | 2010-07-29 | 2015-04-14 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as LSD1 inhibitors |
GB201106829D0 (en) * | 2011-04-21 | 2011-06-01 | Proximagen Ltd | Heterocyclic compounds |
WO2013033688A1 (en) * | 2011-09-01 | 2013-03-07 | The Brigham And Women's Hospital, Inc. | Treatment of cancer |
AR088351A1 (es) * | 2011-10-31 | 2014-05-28 | Lilly Co Eli | Analogos de pirazol sustituidos |
RS59668B1 (sr) * | 2012-05-04 | 2020-01-31 | Samumed Llc | 1h-pirazolo[3,4-b]piridini i njihova terapeutska upotreba |
WO2013175789A1 (ja) | 2012-05-24 | 2013-11-28 | 出光興産株式会社 | 有機エレクトロルミネッセンス素子用材料、及びそれを用いた有機エレクトロルミネッセンス素子 |
-
2014
- 2014-12-10 EP EP22201620.6A patent/EP4257591A3/en active Pending
- 2014-12-10 FI FIEP14868829.4T patent/FI3080100T3/fi active
- 2014-12-10 PT PT148688294T patent/PT3080100T/pt unknown
- 2014-12-10 WO PCT/US2014/069562 patent/WO2015089192A1/en active Application Filing
- 2014-12-10 MX MX2016007585A patent/MX2016007585A/es active IP Right Grant
- 2014-12-10 DK DK14868829.4T patent/DK3080100T3/da active
- 2014-12-10 US US15/103,024 patent/US9944636B2/en active Active
- 2014-12-10 HR HRP20230086TT patent/HRP20230086T1/hr unknown
- 2014-12-10 PL PL14868829.4T patent/PL3080100T3/pl unknown
- 2014-12-10 SI SI201432008T patent/SI3080100T1/sl unknown
- 2014-12-10 ES ES14868829T patent/ES2935746T3/es active Active
- 2014-12-10 EP EP14868829.4A patent/EP3080100B1/en active Active
- 2014-12-10 LT LTEPPCT/US2014/069562T patent/LT3080100T/lt unknown
- 2014-12-10 CA CA2933480A patent/CA2933480C/en active Active
- 2014-12-10 JP JP2016538535A patent/JP6430512B2/ja active Active
- 2014-12-10 RS RS20230070A patent/RS63939B1/sr unknown
- 2014-12-10 CA CA3161836A patent/CA3161836A1/en active Pending
- 2014-12-10 HU HUE14868829A patent/HUE061252T2/hu unknown
-
2016
- 2016-06-09 MX MX2020010496A patent/MX2020010496A/es unknown
-
2018
- 2018-02-20 US US15/900,737 patent/US10131664B2/en active Active
- 2018-10-22 US US16/166,832 patent/US10385051B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
MX2020010496A (es) | 2020-10-28 |
SI3080100T1 (sl) | 2023-04-28 |
HRP20230086T1 (hr) | 2023-03-31 |
CA3161836A1 (en) | 2015-06-18 |
WO2015089192A1 (en) | 2015-06-18 |
US20190055242A1 (en) | 2019-02-21 |
EP3080100B1 (en) | 2022-11-30 |
JP2017502940A (ja) | 2017-01-26 |
EP3080100A4 (en) | 2017-09-06 |
RS63939B1 (sr) | 2023-02-28 |
US10385051B2 (en) | 2019-08-20 |
EP3080100A1 (en) | 2016-10-19 |
MX2016007585A (es) | 2016-12-16 |
HUE061252T2 (hu) | 2023-05-28 |
EP4257591A2 (en) | 2023-10-11 |
LT3080100T (lt) | 2023-02-27 |
US9944636B2 (en) | 2018-04-17 |
US20180179204A1 (en) | 2018-06-28 |
PL3080100T3 (pl) | 2023-03-06 |
CA2933480A1 (en) | 2015-06-18 |
EP4257591A3 (en) | 2023-11-22 |
JP6430512B2 (ja) | 2018-11-28 |
ES2935746T3 (es) | 2023-03-09 |
PT3080100T (pt) | 2023-01-19 |
US20160304516A1 (en) | 2016-10-20 |
FI3080100T3 (fi) | 2023-03-15 |
US10131664B2 (en) | 2018-11-20 |
CA2933480C (en) | 2022-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3080100T3 (da) | Hæmmere af lysinspecifik demethylase-1 | |
DK3371171T3 (da) | Inhibitorer af RET | |
DK3160956T3 (da) | Inhibitorer af lysin-specifik demethylase-1 | |
DK3027618T3 (da) | Polymorf af syk-hæmmere | |
DK3102576T3 (da) | Dihydropyrrolopyridininhibitorer af ror-gamma | |
DK3511319T3 (da) | Hæmmere af lysinspecifik demethylase-1 | |
DK2968208T3 (da) | Behandling af kataplexi | |
DK3137169T3 (da) | Hæmmere af lysin-specifik demethylase-1 | |
DK3068776T3 (da) | Inhibitorer af replikation af influenzavira | |
DK2961388T3 (da) | Kombinationer af lægemidler | |
AR095266A1 (es) | Inhibidores de bromodominios tetraciclicos | |
DK3290407T3 (da) | Bromodomæneinhibitorer | |
DK3030323T3 (da) | Kdm1a-inhibitorer til behandlingen af sygdom | |
DK3087183T3 (da) | Modulation af angiopoietin-3-lignende ekspression | |
DK3611262T3 (da) | Fremgangsmåder til sekvensering af immunrepertoire | |
DK2845905T3 (da) | Fremstilling af oligosaccharider | |
DK2970954T3 (da) | Modifikation af polypeptider | |
DK2981255T3 (da) | Terapeutiske anvendelser af empagliflozin | |
DK2961766T3 (da) | Kvantificering af vaccinesammensætninger | |
DK3008039T3 (da) | Krystallinsk form af en mdm2-inhibitor | |
DK2968221T3 (da) | Farmaceutisk sammensætning af s-ketaminhydrochlorid | |
DK3068854T4 (da) | Fjernelse af uønskede propanolbestanddele | |
DK3021838T3 (da) | Behandling af fedme | |
DK3010895T3 (da) | Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner | |
DK3626270T3 (da) | Behandling af kardiovaskulære sygdomme |